Cargando…

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC

SET binding protein 1 (SETBP1) plays crucial roles in various biological processes; however, its involvement in cancer immune checkpoint inhibitor (ICI) treatments has never been studied. In this study, we collected a total of 631 melanoma and 109 non-small cell lung cancer (NSCLC) samples treated w...

Descripción completa

Detalles Bibliográficos
Autores principales:	An, Fengxiao, Zhang, Wenjing, Guo, Yuxian, Shi, Fuyan, Kong, Yujia, Tang, Liguo, Han, Caijing, Wang, Qinghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457048/ https://www.ncbi.nlm.nih.gov/pubmed/37535001 http://dx.doi.org/10.18632/aging.204913

Ejemplares similares

Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations
por: Zhang, Wenjing, et al.
Publicado: (2022)

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021)

HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer
por: Zhang, Wenjing, et al.
Publicado: (2022)

Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma
por: Shi, Fuyan, et al.
Publicado: (2021)

Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients
por: Wang, Qinghua, et al.
Publicado: (2022)

Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer
por: Li, Zhenpeng, et al.
Publicado: (2022)

Identification of a novel de novo mutation of SETBP1 and new findings of SETBP1 in tumorgenesis
por: Wang, Hongdan, et al.
Publicado: (2023)

Somatic SETBP1 mutations in myeloid malignancies
por: Makishima, Hideki, et al.
Publicado: (2013)

Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
por: Chong, Wei, et al.
Publicado: (2020)

SETBP1 Mutations Drive Leukemic Transformation in ASXL1-Mutated MDS
por: Inoue, Daichi, et al.
Publicado: (2014)

Novel SETBP1 mutation in a chinese family with intellectual disability
por: Wang, Le, et al.
Publicado: (2023)

CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia
por: Cui, Yajuan, et al.
Publicado: (2014)

SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome
por: Linder, Katherine, et al.
Publicado: (2017)

Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies
por: Acuna-Hidalgo, Rocio, et al.
Publicado: (2017)

Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma
por: Wang, Qinghua, et al.
Publicado: (2021)

SETBP1 dysregulation in congenital disorders and myeloid neoplasms
por: Coccaro, Nicoletta, et al.
Publicado: (2017)

The Role of SETBP1 in Gastric Cancer: Friend or Foe
por: Fang, Fujin, et al.
Publicado: (2022)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers
por: Ji, Wenxiang, et al.
Publicado: (2022)

Identification of SETBP1 Mutations by Gene Panel Sequencing in Individuals With Intellectual Disability or With “Developmental and Epileptic Encephalopathy”
por: Leonardi, Emanuela, et al.
Publicado: (2020)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia
por: Hu, WangQiang, et al.
Publicado: (2015)

Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature
por: Wang, L., et al.
Publicado: (2015)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
por: Li, Ji, et al.
Publicado: (2022)

Myb expression is critical for myeloid leukemia development induced by Setbp1 activation
por: Nguyen, Nhu, et al.
Publicado: (2016)

Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation
por: Nguyen, Nhu, et al.
Publicado: (2021)

Putative Roles of SETBP1 Dosage on the SET Oncogene to Affect Brain Development
por: Antonyan, Lilit, et al.
Publicado: (2022)

Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia
por: Cui, Yajuan, et al.
Publicado: (2015)

Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group
por: Bresolin, Silvia, et al.
Publicado: (2016)

ASXL1 and SETBP1 mutations promote leukaemogenesis by repressing TGFβ pathway genes through histone deacetylation
por: Saika, Makoto, et al.
Publicado: (2018)

Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma
por: Patterson, Andrew, et al.
Publicado: (2022)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

An aging‐related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma
por: Zhang, Wenjing, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
por: Passiglia, Francesco, et al.
Publicado: (2021)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?
por: Bronte, Giuseppe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5rh1mskd600h0udmilioa73hc0